Lincotek announced that it has appointed Gianluca Fioravanti as global general manager of its Medical Division, a global solution partner for the orthopedic market.

Fioravanti assumed the role as of today and will report directly to Group CEO Andrea Colombo. He will lead development and execution of the company’s global growth strategy and ensure operational implementation across all regions.

He brings over 25 years of international experience to the Group, serving in senior leadership roles in operations, engineering, and general management in the medical sector. Fioravanti previously worked for a range of global businesses including Pfizer, Baxter, Novartis, GSK Vaccines, and Johnson & Johnson.

“Gianluca brings extensive experience of highly regulated and technologically advanced environments, specifically in the orthopedic industry,” said Colombo. “His proven track record of managing complex international environments and driving transformation programs will be highly significant as we work to optimize the service we provide to customers. This will further reinforce our role as a trusted partner in helping them navigate increasingly complex challenges. We’re thrilled to have him on board.”

Most recently at Jabil Healthcare, he served as senior operations global director, overseeing 12 manufacturing sites in Europe and the U.S. He managed over 4,000 employees.

It is truly an honor to join Lincotek at such an important moment in the company’s evolution,” said Fioravanti. “I am genuinely inspired by the dedication and expertise of the teams within the Medical Division, who represent an extraordinary wealth of professionalism and passion. Together, we aim to strengthen our global impact while accelerating innovation across the entire value chain – from advancing our manufacturing technologies to delivering increasingly sophisticated solutions for our OEM partners. I am excited to collaborate with these exceptional teams to drive further progress and create even greater value for our customers in the years ahead.”

Earlier this year, Lincotek’s Medical Division received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpineLinc anterior cervical implant system, which is manufactured at the company’s Memphis, Tenn. facility.